ESMO 2023: New online educational programme for kidney cancer nurses
Action Kidney Cancer have been involved with the development of [...]
Action Kidney Cancer at the ESMO Congress
Steve Pointon, person centred counsellor kidney cancer patient and one of [...]
ESMO Virtual 2020: Impact of immunotherapy on quality of life
In this video interview, Dr Jeffrey Kirshner from the Haematology-Oncology Associates [...]
Burnout among cancer professionals during COVID-19
Two online surveys presented at the European Society of Medical [...]
ESMO Virtual 2020: Circulating tumour DNA in metastatic kidney cancer patients
In a paper presented at this year’s European Society of [...]
ESMO Virtual 2020: Biomarker-guided therapy in metastatic kidney cancer
Yesterday, findings from the phase 2 biomarker trial, BIONIKK, were [...]
ESMO Virtual 2020: HIF-2a MK-6482 in Von Hippel-Lindau Disease and kidney cancer
At the European Society of Medical Oncology (ESMO) Virtual Congress [...]
ESMO Virtual 2020: Cabozantinib plus atezolizumab in non-clear cell kidney cancer
Non-clear cell renal cell carcinoma (RCC) accounts for about 25% [...]
ESMO Virtual 2020: Nivolumab plus cabozantinib for first-line advanced kidney cancer
At the European Society of Medical Oncology (ESMO) Virtual Congress [...]
ESMO Virtual 2020: Four-year follow-up data from nivolimuab plus ipilimumab in metastatic kidney cancer
Over the past 2 years, the use of combination therapies [...]
